Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy

IL13Rα2 is an attractive target due to its overexpression in a variety of cancers and rare expression in healthy tissue, motivating expansion of interleukin 13 (IL13)–based chimeric antigen receptor (CAR) T cell therapy from glioblastoma into systemic malignancies. IL13Rα1, the other binding partner...

Descripción completa

Detalles Bibliográficos
Autores principales: Stern, Lawrence A., Gholamin, Sharareh, Moraga, Ignacio, Yang, Xin, Saravanakumar, Supraja, Cohen, Joseph R., Starr, Renate, Aguilar, Brenda, Salvary, Vanessa, Hibbard, Jonathan C., Kalbasi, Anusha, Shepphird, Jennifer K., O’Hearn, James, Garcia, K. Christopher, Brown, Christine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388138/
https://www.ncbi.nlm.nih.gov/pubmed/35939683
http://dx.doi.org/10.1073/pnas.2112006119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388138/
https://www.ncbi.nlm.nih.gov/pubmed/35939683
http://dx.doi.org/10.1073/pnas.2112006119

Ejemplares similares